Pfizer partners with Clear Creek Bio to develop oral COVID-19 drug
(VOVWORLD) - Pfizer and Clear Creek Bio on Tuesday announced a collaboration to identify a potential drug candidate and develop a new class of oral treatment against COVID-19, as Pfizer seeks to expand its anti-infective pipeline.
 Pfizer company logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. (Photo: REUTERS) |
Charlotte Allerton, Pfizer's chief scientific officer, said COVID-19 has "the potential to remain a global health concern for years to come".
Pfizer already has a COVID antiviral pill Paxlovid, which the drugmaker expects to generate about 22 billion USD in revenue this year.